


# Post hoc analysis provides new insights on sacubitril/valsartan in myocardial infarction

29 August 2022



complicated by a reduced left ventricular ejection fraction (

Credit: Unsplash/CC0 Public Domain

Sacubitril/valsartan is superior to ramipril in high-risk survivors of acute myocardial infarction, according to a post hoc win ratio analysis of the PARADISE-MI trial presented in [a Hot Line session](#) on 29 August at ESC Congress 2022.

Study author Dr. Otavio Berwanger of the Academic Research Organization (ARO), Hospital Israelita Albert Einstein, Sao Paulo, Brazil said, "The win ratio was introduced in 2012 as a novel approach for examining composite endpoints in [clinical trials](#). The win ratio accounts for both the clinical relevance and timing of individual components of an endpoint—more serious events are given a higher priority and are analyzed first—making it a useful method for analyzing composite outcomes in cardiovascular trials. Applying this method to the PARADISE-MI trial extends our understanding of the effects of sacubitril/valsartan in patients with acute myocardial [infarction](#)."

The primary results of the PARADISE-MI trial were previously reported. The trial randomly assigned 5,661 patients with acute myocardial infarction

APA citation: Post hoc analysis provides new insights on sacubitril/valsartan in myocardial infarction (2022, August 29) retrieved 1 November 2022 from <https://medicalxpress.com/news/2022-08-hoc-analysis-insights-sacubitrilvalsartan-myocardial.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*